Banned in Himachal, YL Pharma Under Rajasthan Scanner After Spurious Drug Detection
Jaipur: In a major revelation, it has emerged that YL Pharma, the pharmaceutical company whose medicines were recently declared spurious in Rajasthan, had already been barred from manufacturing operations in Himachal Pradesh earlier this year, according to state drug regulatory authorities.
The company, YL Pharma, based in Baddi, Himachal Pradesh, had its production activities suspended by the Himachal state government on March 29, according to officials from the Drug Control Office in Dholpur and the state health department.
The matter came to light after a drug sample of Levocetirizine Dihydrochloride tablets (brand name Wincet-L, batch number YLT-25023) manufactured by YL Pharma was collected by the Drug Control Officer in Dholpur. Tests conducted at the Government Analyst Drug Testing Laboratory in Jaipur found the sample to be spurious, prompting immediate action from authorities.
Following the confirmation, the Rajasthan Health Department issued a statewide alert on October 31, notifying all drug controllers about the Himachal government’s suspension of YL Pharma’s licence. The department also launched a sweeping inspection drive across Rajasthan to trace and remove the company’s medicines from the market.
As part of the intensified crackdown, drug control officials inspected 24 pharmaceutical firms across the state. Stocks of Wincet-L tablets were banned, and spurious medicines worth around ₹20 lakh were seized during the raids.
Health Secretary (Health) Gayatri Rathore said that the department has tightened vigilance across manufacturing units and supply chains in light of growing concerns about the quality of medicines being distributed in India. She added that Rajasthan’s drug regulatory teams are conducting regular inspections to ensure patient safety and compliance with drug manufacturing norms.
According to a recent media report by The Times of India, authorities have emphasized that stringent action will continue against firms found violating drug safety standards.
